A patient with advanced Stage 3 chronic kidney disease presents with hyperkalemia, anemia, and metabolic acidosis. Which intervention should the nurse prioritize to address the patient's most immediate risk?

D) Obtain an order for Kayexalate to reduce serum potassium levels

A) Administer erythropoiesis-stimulating agents to manage anemia

B) Educate the patient on a low-potassium diet to prevent further hyperkalemia

C) Administer sodium bicarbonate to correct metabolic acidosis

D) Obtain an order for Kayexalate to reduce serum potassium levels

A patient with Stage 3 chronic kidney disease (CKD) presents with fatigue, swelling in the legs, and laboratory findings of hyperkalemia, anemia, and metabolic acidosis. Which of the following nursing interventions should be prioritized to address the patient's current condition?

B) Initiate a low-potassium diet and administer sodium polystyrene sulfonate to manage hyperkalemia.

A) Administer erythropoiesis-stimulating agents to manage anemia and improve energy levels.

B) Initiate a low-potassium diet and administer sodium polystyrene sulfonate to manage hyperkalemia.

C) Provide supplemental bicarbonate to correct metabolic acidosis and alleviate headaches.

D) Monitor fluid intake and administer loop diuretics to manage fluid overload and leg swelling.

A patient with chronic kidney disease has recently been treated for hyperkalemia and anemia but continues to experience fatigue and tachycardia. Which of the following nursing actions is most appropriate to address the ongoing hyperkalemia and prevent further cardiac complications?

B) Administer a potassium-binding agent as prescribed.

A) Increase dietary potassium intake to balance electrolytes.

B) Administer a potassium-binding agent as prescribed.

C) Encourage the patient to engage in regular physical exercise to improve fatigue.

D) Withhold all diuretics until serum potassium levels normalize.

A patient with chronic kidney disease is experiencing hyperkalemia with elevated serum potassium levels and ECG changes. Despite dietary modifications and medication adjustments, the potassium levels remain high, and the patient reports persistent fatigue and new episodes of palpitations. Which nursing intervention should be prioritized to address the patient's current condition?

B) Administer a potassium-binding agent to reduce serum potassium levels effectively.

A) Increase the dosage of erythropoiesis-stimulating agents to improve hemoglobin levels further.

B) Administer a potassium-binding agent to reduce serum potassium levels effectively.

C) Encourage the patient to engage in more physical activity to alleviate fatigue.

D) Monitor the patient's fluid intake closely to prevent potential volume overload.

A patient with chronic kidney disease and poorly controlled hypertension is experiencing frequent premature ventricular contractions (PVCs) and has been found to have mild left ventricular hypertrophy. Which nursing intervention should be prioritized to address the patient's current condition?

B) Monitor blood pressure closely and collaborate with the healthcare provider to adjust antihypertensive medications.

A) Encourage a high-potassium diet to support cardiac function.

B) Monitor blood pressure closely and collaborate with the healthcare provider to adjust antihypertensive medications.

C) Advise the patient to reduce fluid intake to manage hypertension.

D) Increase physical activity to promote cardiovascular health.

A patient with chronic kidney disease and poorly controlled hypertension presents with mild left ventricular hypertrophy and frequent premature ventricular contractions (PVCs). Given these findings, what is the priority nursing intervention to prevent further cardiac complications?

A) Administer a prescribed beta-blocker to manage tachycardia and reduce cardiac workload.

B) Educate the patient on increasing dietary potassium to counteract PVCs.

C) Encourage the patient to increase physical activity to improve cardiovascular health.

D) Initiate a sodium-restricted diet to manage hypertension and prevent fluid retention.

A patient with a history of hypertension and recent evidence of left ventricular hypertrophy presents with new symptoms of fatigue, shortness of breath, and laboratory findings indicating hyperkalemia and declining renal function. Which of the following nursing interventions should be prioritized to address the patient's current condition?

C) Prepare to administer a loop diuretic and monitor renal function closely.

A) Administer a potassium-sparing diuretic to manage fluid overload.

B) Implement a low-potassium diet and educate the patient on avoiding potassium-rich foods.

C) Prepare to administer a loop diuretic and monitor renal function closely.

D) Increase antihypertensive medications to achieve better blood pressure control.

A patient with a history of hypertension and chronic kidney disease presents with progressive fatigue, shortness of breath on exertion, and signs of fluid overload. The patient's lab results indicate hyperkalemia and worsening renal function. Which nursing intervention is most appropriate to prioritize at this time?

A) Administer the prescribed diuretic and closely monitor urine output and renal function.

B) Increase dietary potassium intake to counteract the effects of the potassium-binding agent.

C) Withhold all antihypertensive medications until blood pressure stabilizes.

D) Encourage the patient to increase fluid intake to help with kidney perfusion.

A patient with chronic kidney disease has been started on a diuretic and a potassium-binding agent. Recent laboratory tests show a serum potassium level of 5.2 mEq/L and stable creatinine at 2.3 mg/dL. The healthcare team is considering additional antihypertensive therapy due to persistent hypertension with blood pressure readings of 158/90 mmHg. Which intervention is most appropriate to address the patient's current condition?

B) Initiate a calcium channel blocker to provide additional antihypertensive effect.

A) Increase the dose of the current diuretic to enhance blood pressure control.

B) Initiate a calcium channel blocker to provide additional antihypertensive effect.

C) Add an angiotensin receptor blocker to further protect kidney function.

D) Focus on dietary modifications to reduce potassium intake.

A patient with chronic kidney disease and hypertension is being managed with a diuretic, potassium-binding agent, and other medications. Recent diagnostic tests show a serum potassium level of 5.2 mEq/L and persistent hypertension with average blood pressure readings of 158/90 mmHg. Which nursing intervention is most appropriate to address the patient's current condition?

D) Collaborate with the healthcare provider to initiate a calcium channel blocker.

A) Increase the dosage of the potassium-binding agent to further lower potassium levels.

B) Educate the patient on a low-potassium diet to prevent hyperkalemia.

C) Encourage the patient to limit fluid intake to reduce blood pressure.

D) Collaborate with the healthcare provider to initiate a calcium channel blocker.

chronic kidney disease - Nursing Case Study

Pathophysiology

• Primary mechanism: Chronic kidney disease (CKD) primarily stems from nephron loss due to conditions like diabetes and hypertension. These conditions cause glomerular damage, reducing filtration ability and leading to progressive nephron scarring (glomerulosclerosis).

• Secondary mechanism: As nephron function declines, compensatory hyperfiltration in remaining nephrons occurs, increasing intraglomerular pressure. This exacerbates nephron injury and accelerates CKD progression by further promoting glomerular damage and fibrosis.

• Key complication: Reduced nephron function leads to impaired excretion of waste products and fluid imbalance, resulting in uremia and hypertension. These complications can escalate to cardiovascular disease, a leading cause of morbidity and mortality in CKD patients.

Patient Profile

Demographics:

52-year-old male, construction worker

History:

• Key past medical history: Hypertension, Type 2 Diabetes, Chronic Kidney Disease Stage 3

• Current medications: Lisinopril, Metformin, Atorvastatin

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increased fatigue and swelling in legs

• Key symptoms: Shortness of breath, decreased urine output, nausea, occasional headaches

• Vital signs: Blood pressure 150/95 mmHg, heart rate 92 bpm, respiratory rate 20 breaths per minute, temperature 98.6°F, oxygen saturation 94% on room air

Section 1

New Diagnostic Results:

Following the patient's complaint of increased fatigue, swelling in his legs, and other symptoms, further diagnostic tests were conducted to assess the progression of his chronic kidney disease and the development of potential complications. The laboratory results reveal a significant increase in serum creatinine to 2.5 mg/dL from a previous 1.8 mg/dL, indicating worsening kidney function. Additionally, blood urea nitrogen (BUN) is elevated at 35 mg/dL, and estimated glomerular filtration rate (eGFR) has decreased to 40 mL/min/1.73m², consistent with advanced Stage 3 CKD. The patient's potassium level is noted to be slightly elevated at 5.5 mEq/L, raising concerns about hyperkalemia, which can have serious cardiac implications.

The urinalysis shows proteinuria with a protein-to-creatinine ratio of 1.5 g/g, suggesting significant kidney damage and increased glomerular permeability. Furthermore, the patient's hemoglobin level has dropped to 10.5 g/dL, indicating anemia, a common complication in CKD due to decreased erythropoietin production. This could contribute to the patient's increased fatigue and shortness of breath. Electrolyte imbalances and the presence of metabolic acidosis (bicarbonate level at 18 mEq/L) were also identified, which could explain the nausea and headaches. The lipid panel shows elevated LDL cholesterol at 160 mg/dL, which requires attention to prevent further cardiovascular risk.

These findings indicate a need for immediate intervention to address the electrolyte imbalances, manage anemia, and optimize blood pressure control. The healthcare team must consider adjusting the patient's medication regimen, including the potential addition of diuretics to manage fluid overload and anemia treatment options such as erythropoiesis-stimulating agents. The patient's cardiovascular risk must also be reassessed, and appropriate lifestyle changes, diet modifications, and possibly lipid-lowering therapy adjustments should be discussed. This comprehensive approach aims to slow CKD progression, alleviate symptoms, and prevent further complications.

Section 2

Change in Patient Status:

Following the implementation of initial interventions, including adjustments to the patient's medication regimen to address electrolyte imbalances and anemia, the patient was closely monitored for changes in clinical status. Within a week, the nursing team observed that the patient's lower extremity edema had shown some reduction, suggesting a positive response to the diuretic therapy. However, the patient continued to report persistent fatigue and new episodes of palpitations. A repeat set of vital signs revealed tachycardia with a heart rate of 110 bpm, and blood pressure slightly elevated at 150/90 mmHg, indicating the need for further cardiovascular assessment.

Laboratory tests were repeated to track the patient's progress. Serum potassium levels remained elevated at 5.3 mEq/L, and new ECG findings confirmed the presence of peaked T-waves, raising concern for ongoing hyperkalemia. The patient's hemoglobin level improved marginally to 11.0 g/dL following erythropoiesis-stimulating agent therapy, yet the patient still experienced significant fatigue. Additionally, repeat metabolic panel results showed persistent metabolic acidosis with a bicarbonate level of 19 mEq/L, despite dietary modifications and bicarbonate therapy.

These findings suggest the need for continued multidisciplinary management and highlight the importance of adjusting the treatment plan to address unresolved issues. The healthcare team must now consider evaluating the patient's current medication dosages, particularly looking into potassium-binding agents to manage hyperkalemia more effectively. Furthermore, exploring other potential causes for the patient's tachycardia, like potential volume overload or underlying cardiac issues, is crucial. The team should also reassess the patient's diet and lifestyle to further control blood pressure and cholesterol levels. Through careful monitoring and ongoing adjustments, the goal is to stabilize the patient's condition and prevent further complications, paving the way for the next steps in managing his chronic kidney disease.

Section 3

New Diagnostic Results:

Following the persistent symptoms and the concerning ECG findings, the healthcare team decided to conduct more comprehensive diagnostic tests to uncover any underlying issues contributing to the patient's current condition. An echocardiogram was performed to assess cardiac function, revealing mild left ventricular hypertrophy, suggesting pressure overload likely due to poorly controlled hypertension. This finding indicates the need for tighter blood pressure management and potentially adjusting the patient's antihypertensive regimen to include agents that could provide additional cardiac protection.

Moreover, a 24-hour Holter monitor was deployed to better evaluate the cause of the patient's tachycardia and palpitations. Results showed frequent premature ventricular contractions (PVCs), which may be exacerbated by the patient's elevated potassium levels and could further complicate cardiac function. The team recognized the urgency of addressing hyperkalemia more aggressively, perhaps considering the introduction of a potassium-binding agent or initiating a low-potassium diet to mitigate this risk.

Given these findings, the multidisciplinary team must reassess and refine the treatment strategy, focusing on optimizing cardiovascular health while managing chronic kidney disease. This includes recalibrating medication dosages, enhancing dietary interventions, and coordinating with cardiology for potential further workup or treatment options. The patient's journey underscores the complexity of interconnected systems and emphasizes the need for holistic management to prevent further complications and promote overall well-being.

Section 4

Change in Patient Status

A few days after the implementation of the revised treatment plan, which included a combination of adjusted antihypertensive medications and dietary modifications, the patient presented with new symptoms of progressive fatigue and shortness of breath on exertion. During a follow-up visit, the patient's vital signs indicated a blood pressure of 160/92 mmHg, heart rate of 110 beats per minute, and respiratory rate of 24 breaths per minute. Physical examination revealed mild pedal edema and crackles at the lung bases, suggestive of fluid overload. These findings raised concerns about the patient's cardiac function, particularly in light of the recent echocardiogram results indicating left ventricular hypertrophy.

Laboratory tests showed a further increase in serum potassium to 5.8 mEq/L, despite dietary interventions, indicating that hyperkalemia was not adequately controlled. Additionally, creatinine levels had risen to 2.3 mg/dL from the previous 2.0 mg/dL, reflecting a possible decline in renal function. The patient’s hemoglobin level was noted at 10.5 g/dL, hinting at anemia of chronic disease, which might be contributing to the increased fatigue. Given these developments, the healthcare team decided to initiate a diuretic cautiously, balancing the need to manage fluid overload with the risk of exacerbating kidney function decline. Furthermore, the introduction of a potassium-binding agent was prioritized to address the persistent hyperkalemia.

The patient's evolving condition required an immediate re-evaluation of the management approach, with particular emphasis on achieving tighter control of blood pressure and potassium levels while protecting renal function. The multidisciplinary team considered consulting nephrology for potential adjustments in the chronic kidney disease treatment regimen, including erythropoiesis-stimulating agents for anemia management, and cardiology to explore further strategies to address the patient's cardiovascular risk. This situation underscores the importance of continuous monitoring and dynamic adjustment of treatment plans to prevent further complications and support the patient's overall health trajectory.

Section 5

New Diagnostic Results

Following the initiation of a diuretic to manage fluid overload and a potassium-binding agent for hyperkalemia, the healthcare team conducted a series of follow-up diagnostic tests to assess the patient's response to these interventions. The repeat laboratory tests revealed that the serum potassium level had decreased to 5.2 mEq/L, indicating a partial improvement, though still at the upper limit of normal. The patient's creatinine level remained stable at 2.3 mg/dL, suggesting that renal function had not deteriorated further with the introduction of the diuretic; however, vigilance was advised due to the delicate balance required for fluid management. The complete blood count showed a slight decrease in hemoglobin to 10.2 g/dL, reinforcing the need for a potential erythropoiesis-stimulating agent to address the anemia that could be aggravating the patient's fatigue.

An updated echocardiogram demonstrated no significant change in the left ventricular hypertrophy, but there was mild concentric remodeling, raising concerns about the potential progression of cardiac complications. The patient's 24-hour ambulatory blood pressure monitoring indicated persistent hypertension with average readings of 158/90 mmHg, despite medication adjustments. This prompted the consideration of adding another antihypertensive class, such as a calcium channel blocker, to achieve better cardiovascular and renal protection.

These diagnostic results emphasized the need for a nuanced approach to the patient's care, requiring ongoing adjustment of pharmacotherapy and close monitoring of electrolytes, renal function, and cardiovascular status. The healthcare team decided to involve nephrology for further management of the chronic kidney disease and cardiology to refine the antihypertensive regimen, ensuring that the patient's treatment plan remained proactive in preventing further complications. The next steps in the patient's journey would focus on optimizing these interventions to stabilize the patient's condition and improve quality of life.